Humanigen WKN: A2QEQW ISIN: US4448632038 Kürzel: HGEN Forum: Aktien Thema: Hauptdiskussion

Respekt.... traue ich mich nicht... dem fallenden Messer hinterhergreifen

Hier würde ich auch erstmal Nachrichten abwarten und lieber ein paar Prozent liegen lassen als blind nachzukaufen.

Momentan geht alles Bach runter

Aber die gute Zeiten kommen wieder die Frage? Wann?

Hier wird meiner Meinung nach nix mehr zurückkommen. Lenzi scheint einfach ein sch... Medikament mit geringer oder keiner Wirkung zu sein. Liegen lassen und vergessen.

So ist es..leider

Burn baby burn ❤️‍🔥. Die Kohle ist futsch..So ein Mist

Heftig

Völlig übertrieben. Der Brief war doch absehbar. Den verschickt die SEC an alle im Nasdaq die 3 Monate oder so unter einem Dollar stehen.

Übelst..Was ist passiert?

Jetz brauch ich 1000% für EK 😅 ich kaufe bei den Kursen nicht nach, bevor es keine positiven News gibt

Puh

Ist doch nur Rausschmiss aus dem Nasdaq, dann wird halt über Otc gehandelt. Oder die machen wie alle anderen einen RS

Delisting in 180 Tagen, wenn der Preis nicht über 1 Dollar steigt 😭

On August 24, 2022, Humanigen, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock, par value $0.001 per share (the “Common Stock”), which continues to trade on The Nasdaq Capital Market under the symbol “HGEN.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until February 20, 2023, to regain compliance. If at any time before February 20, 2023, the closing bid price of the Company’s Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter will be resolved. If the Company does not regain compliance during the compliance period ending February 20, 2023, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements.